Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,899 shares of the medical equipment provider’s stock after buying an additional 27 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Intuitive Surgical were worth $3,002,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. PDS Planning Inc lifted its stake in shares of Intuitive Surgical by 4.5% in the 4th quarter. PDS Planning Inc now owns 1,343 shares of the medical equipment provider’s stock worth $453,000 after acquiring an additional 58 shares during the period. RWA Wealth Partners LLC increased its position in Intuitive Surgical by 1,354.5% during the fourth quarter. RWA Wealth Partners LLC now owns 22,327 shares of the medical equipment provider’s stock worth $7,532,000 after acquiring an additional 20,792 shares during the period. Sage Mountain Advisors LLC boosted its stake in Intuitive Surgical by 6.1% during the fourth quarter. Sage Mountain Advisors LLC now owns 1,330 shares of the medical equipment provider’s stock worth $449,000 after buying an additional 77 shares in the last quarter. North Star Asset Management Inc. boosted its stake in shares of Intuitive Surgical by 3.8% in the 4th quarter. North Star Asset Management Inc. now owns 22,294 shares of the medical equipment provider’s stock valued at $7,521,000 after purchasing an additional 819 shares in the last quarter. Finally, MCF Advisors LLC lifted its position in Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wells Fargo & Company increased their target price on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Jefferies Financial Group increased their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday. Citigroup raised their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus raised their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Piper Sandler lifted their price target on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Stock Up 2.4 %

ISRG stock traded up $8.74 during midday trading on Tuesday, hitting $377.67. The company’s stock had a trading volume of 788,134 shares, compared to its average volume of 1,663,087. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The stock’s 50-day moving average price is $386.57 and its 200 day moving average price is $344.41. The stock has a market cap of $133.87 billion, a price-to-earnings ratio of 68.22, a PEG ratio of 5.69 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.00 EPS. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the completion of the transaction, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Myriam Curet sold 4,318 shares of the stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the sale, the chief executive officer now owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.80% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.